Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Application Number	Priority Date	Filing Date	Title
US201562250016P	2015-11-03	2015-11-03
PCT/US2016/059893WO2017079150A1 (en)	2015-11-03	2016-11-01	Subcutaneous formulations of anti-cd38 antibodies and their uses

Publication Number	Publication Date
SG11201803678SAtrue SG11201803678SA (en)	2018-05-30

Family

ID=58634408

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201803678SASG11201803678SA (en)	2015-11-03	2016-11-01	Subcutaneous formulations of anti-cd38 antibodies and their uses

Country Status (39)

Country	Link
US (8)	US10385135B2 (en)
EP (4)	EP4516319A3 (en)
JP (4)	JP7027321B2 (en)
KR (1)	KR20180067693A (en)
CN (3)	CN108472369A (en)
AR (1)	AR106582A1 (en)
AU (2)	AU2016350717B2 (en)
BR (1)	BR112018008901A8 (en)
CA (2)	CA3233159A1 (en)
CL (1)	CL2018001202A1 (en)
CO (1)	CO2018005616A2 (en)
CR (1)	CR20180251A (en)
CY (2)	CY1124004T1 (en)
DK (2)	DK3827845T3 (en)
EA (2)	EA201891083A1 (en)
EC (1)	ECSP18040758A (en)
ES (2)	ES2862425T3 (en)
HR (2)	HRP20220680T1 (en)
HU (1)	HUE053366T2 (en)
IL (1)	IL259075A (en)
LT (2)	LT3827845T (en)
MA (2)	MA53356B1 (en)
MD (2)	MD3827845T2 (en)
MX (3)	MX387587B (en)
MY (1)	MY202415A (en)
NI (1)	NI201800056A (en)
NZ (1)	NZ780958A (en)
PE (1)	PE20181365A1 (en)
PH (1)	PH12018500950B1 (en)
PL (2)	PL3370770T3 (en)
PT (2)	PT3370770T (en)
RS (2)	RS61651B1 (en)
SG (1)	SG11201803678SA (en)
SI (2)	SI3370770T1 (en)
SM (2)	SMT202100192T1 (en)
SV (1)	SV2018005683A (en)
TW (5)	TWI838196B (en)
WO (1)	WO2017079150A1 (en)
ZA (1)	ZA201907815B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1914242A1 (en)*	2006-10-19	2008-04-23	Sanofi-Aventis	Novel anti-CD38 antibodies for the treatment of cancer
JOP20210044A1 (en)	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	Anti-CD38 . antibody
US9603927B2 (en)	2014-02-28	2017-03-28	Janssen Biotech, Inc.	Combination therapies with anti-CD38 antibodies
US9732154B2 (en)	2014-02-28	2017-08-15	Janssen Biotech, Inc.	Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
ES2890669T3 (en)	2014-09-09	2022-01-21	Janssen Biotech Inc	Combination therapies with anti-CD38 antibodies
SG11201704390PA (en)	2014-12-04	2017-06-29	Janssen Biotech Inc	Anti-cd38 antibodies for treatment of acute myeloid leukemia
KR102602754B1 (en)	2015-05-20	2023-11-14	얀센 바이오테크 인코포레이티드	Anti-CD38 antibodies for treating light chain amyloidosis and other CD38-positive hematological malignancies
CN107708734B (en)	2015-06-22	2022-01-11	詹森生物科技公司	Combination therapy of heme malignancies with anti-CD 38 antibodies and survivin inhibitors
US20170044265A1 (en)	2015-06-24	2017-02-16	Janssen Biotech, Inc.	Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en)	2015-11-03	2020-09-22	Janssen Biotech, Inc.	Subcutaneous formulations of anti-CD38 antibodies and their uses
ES2862425T3 (en)	2015-11-03	2021-10-07	Janssen Biotech Inc	Subcutaneous formulations of anti-CD38 antibodies and their uses
EP3484923A1 (en)	2016-07-15	2019-05-22	Takeda Pharmaceutical Company Limited	Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
DK3631454T3 (en)	2017-05-30	2023-12-04	Bristol Myers Squibb Co	TREATMENT OF LAYER-3 POSITIVE TUMORS
CA3065304A1 (en)*	2017-05-30	2018-12-06	Bristol-Myers Squibb Company	Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
MA50514A (en)	2017-10-31	2020-09-09	Janssen Biotech Inc	HIGH-RISK MULTIPLE MYELOMA TREATMENT METHODS
JP2021510737A (en)	2018-01-12	2021-04-30	武田薬品工業株式会社	Subcutaneous administration of anti-CD38 antibody
CN110144008B (en)*	2018-02-12	2021-03-19	杭州尚健生物技术有限公司	CD38 protein antibody and application thereof
MX2020010144A (en)*	2018-03-28	2020-12-07	Takeda Pharmaceuticals Co	Subcutaneous dosing of anti-cd38 antibodies.
WO2019201894A1 (en)*	2018-04-16	2019-10-24	Merck Patent Gmbh	Additives for protein formulations to improve thermal stability
KR20210011002A (en)	2018-05-16	2021-01-29	얀센 바이오테크 인코포레이티드	Methods of treating cancer and methods of improving the efficacy of T-cell reinduction therapeutics
WO2020022791A1 (en)	2018-07-25	2020-01-30	(주)알테오젠	Novel hyaluronic acid-hydrolyzing enzyme mutant and pharmaceutical composition comprising same
JP7503056B6 (en)	2018-11-07	2024-07-16	メルク・シャープ・アンド・ドーム・エルエルシー	Co-formulation of anti-LAG3 and anti-PD-1 antibodies
EA202191352A1 (en)	2018-11-13	2021-08-11	Янссен Байотек, Инк.	CONTROL OF THE CONTENT OF MICROELEMENTS-METALS DURING THE PRODUCTION OF ANTIBODIES TO CD38
CN111303293B (en)*	2018-11-14	2022-08-30	杭州尚健生物技术有限公司	Fusion protein and application thereof
TWI820270B (en)	2018-12-14	2023-11-01	德商莫菲西斯公司	Antibody formulations
EP3923954A1 (en)	2019-02-12	2021-12-22	Prothena Biosciences Limited	Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells
CA3132780A1 (en)	2019-03-05	2020-09-10	Prothena Biosciences Limited	Methods of treating al amyloidosis
EP3935087A4 (en)*	2019-03-08	2022-12-07	Cedars-Sinai Medical Center	ANTI-CD38 AGENTS FOR DESENSITIZATION AND TREATMENT OF ANTIBODY MEDIATED REJECTION OF ORGAN TRANSPLANTS
WO2020194243A1 (en)*	2019-03-28	2020-10-01	Janssen Biotech, Inc.	Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with lenalidomide and dexamethasone
US20200330593A1 (en)*	2019-03-28	2020-10-22	Janssen Biotech, Inc.	Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone
US20200308297A1 (en)*	2019-03-28	2020-10-01	Janssen Biotech, Inc.	Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
US20200308296A1 (en)*	2019-03-28	2020-10-01	Janssen Biotech, Inc.	Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
US20200316197A1 (en)*	2019-03-28	2020-10-08	Janssen Biotech, Inc.	Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone
US20200330594A1 (en)*	2019-04-19	2020-10-22	Janssen Biotech, Inc.	Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20200397896A1 (en)*	2019-04-19	2020-12-24	Janssen Biotech, Inc.	Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
WO2020212911A2 (en)*	2019-04-19	2020-10-22	Janssen Biotech, Inc.	Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses
WO2020219681A1 (en)*	2019-04-23	2020-10-29	Sanofi	Anti-cd38 antibodies and formulations
US11655302B2 (en)	2019-06-10	2023-05-23	Sanofi	Anti-CD38 antibodies and formulations
WO2020250033A1 (en)*	2019-06-10	2020-12-17	Takeda Pharmaceutical Company Limited	Combination therapies using cd-38 antibodies
BR112022010905A2 (en)*	2019-12-05	2022-09-06	Sanofi Aventis Us Llc	ANTI-CD38 ANTIBODY FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION
IL294453A (en)*	2020-01-16	2022-09-01	Genmab As	Formulations of cd38 antibodies and uses thereof
EP4126952A1 (en)	2020-03-26	2023-02-08	Seagen Inc.	Methods of treating multiple myeloma
WO2021202863A1 (en)*	2020-04-02	2021-10-07	Promab Biotechnologies, Inc.	Human ror-1 antibody and anti-ror-1-car-t cells
US20210338766A1 (en)*	2020-04-29	2021-11-04	Onyx Pharmaceuticals, Inc.	Methods of treating multiple myeloma
BR112022023137A2 (en)*	2020-05-15	2023-02-07	Takeda Pharmaceuticals Co	ADMINISTRATION OF JUICE ACTIVATION ENZYME INHIBITORS AND ANTI-CD38 ANTIBODIES
CN113797161A (en)*	2020-06-11	2021-12-17	上海宝济药业有限公司	Liquid preparation of recombinant human hyaluronidase and application thereof
JP7622088B2 (en)	2020-08-07	2025-01-27	アルテオジェン・インコーポレイテッド	Methods for Producing Recombinant Hyaluronidase
US20220202859A1 (en)*	2020-12-23	2022-06-30	Crispr Therapeutics Ag	Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
EP4272729A4 (en)*	2020-12-30	2025-01-08	Shanghai Bao Pharmaceuticals Co., Ltd.	RECOMBINANT HUMAN HYALURONIDASE FORMULATION AND USE THEREOF
WO2022226130A1 (en)	2021-04-21	2022-10-27	Indapta Therapeutics, Inc.	Methods of treatment and dosing of natural killer cell compositions
US11694876B2 (en)	2021-12-08	2023-07-04	Applied Materials, Inc.	Apparatus and method for delivering a plurality of waveform signals during plasma processing
EP4547269A1 (en)	2022-06-30	2025-05-07	Indapta Therapeutics, Inc.	Combination of engineered natural killer (nk) cells and antibody therapy and related methods
CN119997972A (en)*	2022-07-26	2025-05-13	拜奥卡德联合股份公司	Pharmaceutical composition of anti-CD 20 antibody and application thereof

Family Cites Families (169)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US250016A (en)		1881-11-22		Refrigerating apparatus
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3785186T2 (en)	1986-09-02	1993-07-15	Enzon Lab Inc	BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN.
HUT53672A (en)	1988-02-25	1990-11-28	Gen Hospital Corp	Quick immunoselective cloning process
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
CA2087272C (en)	1990-07-13	2005-10-11	Brian Seed	Cd53 cell surface antigen and use thereof
US5932448A (en)	1991-11-29	1999-08-03	Protein Design Labs., Inc.	Bispecific antibody heterodimers
ES2227512T3 (en)	1991-12-02	2005-04-01	Medical Research Council	PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO.
AU690528B2 (en)	1992-12-04	1998-04-30	Medical Research Council	Multivalent and multispecific binding proteins, their manufacture and use
WO1994017184A1 (en)	1993-01-29	1994-08-04	Schering Corporation	Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
GB9424449D0 (en)	1994-12-02	1995-01-18	Wellcome Found	Antibodies
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
AUPO591797A0 (en)	1997-03-27	1997-04-24	Commonwealth Scientific And Industrial Research Organisation	High avidity polyvalent and polyspecific reagents
WO1998016245A1 (en)	1996-10-15	1998-04-23	Shionogi & Co., Ltd.	Method of autoantibody assay
US6083477A (en)	1996-10-17	2000-07-04	Immunomedics, Inc.	Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
WO2000006194A2 (en)	1997-02-05	2000-02-10	Biotransplant, Inc.	Depletion of cells responsible for antibody-mediated graft rejection
AU745823B2 (en)	1997-05-02	2002-04-11	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Immunotoxins, comprising an onc protein, directed against malignant cells
AU770718B2 (en)	1998-06-05	2004-02-26	Mayo Foundation For Medical Education And Research	Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US7223397B1 (en)	1999-01-07	2007-05-29	Research Development Foundation	Potentiation of anti-CD38-Immunotoxin cytotoxicity
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
US7829693B2 (en)	1999-11-24	2010-11-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a target gene
CN100436425C (en)	2000-02-15	2008-11-26	安斯泰来制药有限公司	Fused imidazolium derivatives
FR2807767B1 (en)	2000-04-12	2005-01-14	Lab Francais Du Fractionnement	MONOCLONAL ANTIBODIES ANTI-D
JP2003535908A (en)	2000-06-22	2003-12-02	アイデックファーマスーティカルズコーポレイション	Bispecific fusion proteins and methods of use to enhance effector cells that kill target cells
EP1174440A1 (en)	2000-07-19	2002-01-23	U-BISys B.V.	A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US20070042436A1 (en)	2000-10-17	2007-02-22	Lund Frances E	CD38 modulated chemotaxis
JP4139214B2 (en)	2000-10-17	2008-08-27	トリュデュインスティチュート，インク．	Chemotaxis regulated by CD38
US6833441B2 (en)	2001-08-01	2004-12-21	Abmaxis, Inc.	Compositions and methods for generating chimeric heteromultimers
US20040166490A1 (en)	2002-12-17	2004-08-26	Morris David W.	Novel therapeutic targets in cancer
AU2003257419B2 (en)	2002-06-13	2010-02-25	Crucell Holland, B.V.	OX40 (CD134) receptor agonistic and therapeutic use
CN1942588B (en)	2003-03-05	2013-06-12	海洋酶公司	Soluble hyaluronidase glycoproteins (sHASEGP), methods for their preparation, their use and pharmaceutical compositions comprising them
WO2004092160A1 (en)	2003-04-15	2004-10-28	Astellas Pharma Inc.	Bromide and its crystal
US7543051B2 (en)	2003-05-30	2009-06-02	Borland Software Corporation	Method of non-intrusive analysis of secure and non-secure web application traffic in real-time
RS20150135A1 (en)	2003-05-30	2015-08-31	Genentech Inc.	Treatment with anti-vegf antibodies
WO2004111233A1 (en)	2003-06-11	2004-12-23	Chugai Seiyaku Kabushiki Kaisha	Process for producing antibody
US7902338B2 (en)	2003-07-31	2011-03-08	Immunomedics, Inc.	Anti-CD19 antibodies
CA2542840A1 (en)	2003-10-22	2005-05-12	University Of Rochester	Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
WO2005044855A2 (en)	2003-11-04	2005-05-19	Chiron Corporation	Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
JP4712724B2 (en)	2003-12-23	2011-06-29	クルセルホランドベーヴェー	Human binding molecule for CD1a
MXPA06008700A (en)	2004-02-06	2007-01-19	Morphosys Ag	Anti-cd38 human antibodies and uses therefor.
RS54056B1 (en)	2004-02-06	2015-10-30	Morphosys Ag	Anti-cd38 human antibodies and uses therefor
SG10201912554TA (en)*	2005-03-23	2020-02-27	Genmab As	Antibodies against cd38 for treatment of multiple myeloma
WO2006106905A1 (en)	2005-03-31	2006-10-12	Chugai Seiyaku Kabushiki Kaisha	Process for production of polypeptide by regulation of assembly
CA3151350A1 (en)	2005-05-09	2006-11-16	E. R. Squibb & Sons, L.L.C.	Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1888647A2 (en)	2005-05-24	2008-02-20	MorphoSys AG	Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
CN103145838A (en)	2005-06-30	2013-06-12	Abbvie公司	IL-12/p40 binding proteins
DK2860192T3 (en)	2005-10-12	2018-01-02	Morphosys Ag	Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
WO2007075326A2 (en)	2005-12-09	2007-07-05	Seattle Genetics, Inc.	Methods of using cd40 binding agents
EP1999154B1 (en)	2006-03-24	2012-10-24	Merck Patent GmbH	Engineered heterodimeric protein domains
EP2035456A1 (en)	2006-06-22	2009-03-18	Novo Nordisk A/S	Production of bispecific antibodies
EP3025712A1 (en)	2006-08-02	2016-06-01	Sunesis Pharmaceuticals, Inc.	Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia
WO2008073160A2 (en)	2006-08-17	2008-06-19	The Trustees Of Columbia University In The City Of New York	Methods for converting or inducing protective immunity
EP3753576A1 (en)	2006-09-26	2020-12-23	Genmab A/S	Combination treatment of cd38-expressing tumors
EP1914242A1 (en)	2006-10-19	2008-04-23	Sanofi-Aventis	Novel anti-CD38 antibodies for the treatment of cancer
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
US7618992B2 (en)	2006-12-29	2009-11-17	Astellas Pharma Inc.	Method of treating cancer by co-administration of anticancer agents
CA2681743A1 (en)*	2007-03-22	2008-09-25	Imclone Llc	Stable antibody formulations
ES2667863T3 (en)	2007-03-29	2018-05-14	Genmab A/S	Bispecific antibodies and their production methods
AU2008232903B9 (en)*	2007-03-30	2013-09-05	Medimmune Llc	Antibodies with decreased deamidation profiles
US20090175847A1 (en)	2007-05-30	2009-07-09	Abbott Laboratories	Humanized antibodies to ab (20-42) globulomer and uses thereof
AU2008260445A1 (en)	2007-06-01	2008-12-11	Biogen Idec Ma Inc.	Cripto binding molecules
CN102131828B (en)	2007-06-18	2015-06-17	默沙东有限责任公司	Antibody against human programmed death receptor PD-1
US20090076249A1 (en)	2007-09-19	2009-03-19	Michel De Weers	Antibodies against CD38 for treatment of multiple myeloma
CA2705263A1 (en)	2007-11-09	2009-05-14	Novartis Ag	Combination therapy with an antagonist anti-cd 40 antibody and cyclophosphamide, doxorubicin, vincristine and prednisone (chop) for treatment of b-cell malignancies
WO2009062504A1 (en)	2007-11-13	2009-05-22	Tnm Farmguard Aps	Secure communication between a client and devices on different private local networks using the same subnet addresses
US8440199B2 (en)	2007-12-12	2013-05-14	Imperial Innovations Limited	Methods for mobilizing mesenchymal stem cells in a patient
WO2009085462A1 (en)	2007-12-19	2009-07-09	Centocor, Inc.	Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
PL2235064T3 (en)	2008-01-07	2016-06-30	Amgen Inc	Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP2011517320A (en)	2008-03-03	2011-06-02	ダイアックスコーポレーション	Metalloprotease 9 binding protein and metalloprotease 2 binding protein
CN101970650B (en)	2008-03-06	2017-07-25	哈洛齐梅公司	Large-scale production of soluble hyaluronidase
TWI532498B (en)	2008-03-17	2016-05-11	巴克斯特保健公司	Combination and method for subcutaneous administration of immunoglobulin and hyaluronic acid
AU2009228616B2 (en)	2008-03-25	2014-07-24	Roche Glycart Ag	Use of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-Hodgkin' s lymphomas
SG187427A1 (en)*	2008-04-14	2013-02-28	Halozyme Inc	Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (en)	2008-04-28	2013-05-01	Halozyme Inc	Super fast-acting insulin compositions
CA2722466A1 (en)	2008-04-29	2009-11-05	Tariq Ghayur	Dual variable domain immunoglobulins and uses thereof
SMT201900278T1 (en)	2008-11-07	2019-07-11	Amgen Res Munich Gmbh	Treatment of acute lymphoblastic leukemia
EP2191842A1 (en)	2008-11-28	2010-06-02	Sanofi-Aventis	Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191843A1 (en)	2008-11-28	2010-06-02	Sanofi-Aventis	Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191841A1 (en)	2008-11-28	2010-06-02	Sanofi-Aventis	Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191840A1 (en)	2008-11-28	2010-06-02	Sanofi-Aventis	Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
US8383778B2 (en)	2009-01-29	2013-02-26	Abbvie Inc.	IL-1 binding proteins
MX2011009362A (en)	2009-03-05	2011-09-26	Abbott Lab	Il-17 binding proteins.
US9067986B2 (en)	2009-04-27	2015-06-30	Oncomed Pharmaceuticals, Inc.	Method for making heteromultimeric molecules
SMT202000092T1 (en)	2009-05-14	2020-05-08	Ambit Biosciences Corp	Spray dried formulation of ac220
US9345661B2 (en)*	2009-07-31	2016-05-24	Genentech, Inc.	Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en)*	2009-09-11	2011-10-19	Hoffmann La Roche	VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
CA2774053C (en)*	2009-09-17	2015-04-28	Baxter Healthcare, S.A.	Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
DK2486141T3 (en)	2009-10-07	2018-04-23	Macrogenics Inc	FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE
EP2327725A1 (en)	2009-11-26	2011-06-01	InflaRx GmbH	Anti-C5a binding moieties with high blocking activity
SG184355A1 (en)	2010-03-01	2012-11-29	Progenics Pharm Inc	Concentrated protein formulations and uses thereof
GB201003701D0 (en)	2010-03-05	2010-04-21	Cilian Ag	System for the expression of a protein
WO2011121588A1 (en)	2010-03-29	2011-10-06	Ben Gurion University Of The Negev Research And Development Authority	Method and system for detecting and monitoring hematological cancer
KR101930964B1 (en)	2010-04-20	2018-12-19	젠맵 에이/에스	Heterodimeric antibody fc-containing proteins and methods for production thereof
CA2797981C (en)	2010-05-14	2019-04-23	Rinat Neuroscience Corporation	Heterodimeric proteins and methods for producing and purifying them
DK2580243T3 (en)	2010-06-09	2020-01-13	Genmab As	ANTIBODIES AGAINST HUMAN CD38
EP2420253A1 (en)	2010-08-20	2012-02-22	Leadartis, S.L.	Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
NZ607473A (en)*	2010-09-27	2014-11-28	Morphosys Ag	Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
KR101973930B1 (en)	2010-11-05	2019-04-29	자임워크스 인코포레이티드	Stable heterodimeric antibody design with mutations in the fc domain
KR20220070586A (en)	2010-11-08	2022-05-31	제넨테크, 인크.	Subcutaneously administered anti-il-6 receptor antibody
US9358233B2 (en)	2010-11-29	2016-06-07	Boehringer Ingelheim International Gmbh	Method for treating acute myeloid leukemia
UA112170C2 (en)	2010-12-10	2016-08-10	Санофі	ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB
JOP20210044A1 (en)	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	Anti-CD38 . antibody
CL2013001944A1 (en)	2010-12-30	2014-09-12	Takeda Pharmaceutical	Isolated antibody that specifically binds to human cd38 and cinomolgo cd38; nucleic acid encoding it; host cell; Method of production; and its use to treat an autoimmune disease.
EP2688887B1 (en)	2011-03-23	2015-05-13	Amgen Inc.	Fused tricyclic dual inhibitors of cdk 4/6 and flt3
AR085934A1 (en)	2011-04-08	2013-11-06	Ab Science	MULTIPLE MYELOMA TREATMENT WITH MASITINIB
US9993529B2 (en)	2011-06-17	2018-06-12	Halozyme, Inc.	Stable formulations of a hyaluronan-degrading enzyme
EP2561868A1 (en)	2011-08-24	2013-02-27	Anton Bernhard Van Oosten	Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field
WO2013028186A1 (en)	2011-08-24	2013-02-28	Oxford Oncology Inc.	Low-dose combination chemotherapy
MX360741B (en)	2011-10-28	2018-11-14	Teva Pharmaceuticals Australia Pty Ltd	Polypeptide constructs and uses thereof.
WO2013083140A1 (en)	2011-12-07	2013-06-13	N.V. Nutricia	Beta-lactoglobulin peptides for treating cow's milk protein allergy
SMT201900630T1 (en)	2011-12-30	2020-01-14	Halozyme Inc	Ph20 polypeptide variants, formulations and uses thereof
CN104159614A (en)*	2012-03-07	2014-11-19	卡迪拉保健有限公司	Pharmaceutical formulations of TNF-alpha antibodies
KR101809858B1 (en)	2012-04-04	2017-12-15	할로자임, 아이엔씨	Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane
JP6448533B2 (en)	2012-05-15	2019-01-09	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Cancer immunotherapy by disrupting PD-1 / PD-L1 signaling
US9682143B2 (en)	2012-08-14	2017-06-20	Ibc Pharmaceuticals, Inc.	Combination therapy for inducing immune response to disease
JP6426093B2 (en)	2012-09-25	2018-11-28	モルフォシス・アーゲー	Combination and use
US9486547B2 (en)	2012-11-05	2016-11-08	Morphosys Ag	Radiolabelled antibody and uses thereof
UA118255C2 (en)	2012-12-07	2018-12-26	Санофі	Compositions comprising anti-cd38 antibodies and lenalidomide
CN105188749B (en)	2012-12-21	2017-12-19	西雅图基因公司	Anti-NTB-A antibodies and related compositions and methods
WO2014105810A1 (en)	2012-12-24	2014-07-03	Abbvie Inc.	Prolactin receptor binding proteins and uses thereof
WO2014142220A1 (en)	2013-03-13	2014-09-18	アステラス製薬株式会社	Anti-tumor agent
US20140271644A1 (en)	2013-03-15	2014-09-18	Memorial Sloan-Kettering Cancer Center	Combination/adjuvant therapy for wt-1-positive disease
PT2992013T (en)	2013-04-29	2020-03-05	Teva Pharmaceuticals Australia Pty Ltd	Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US20140356318A1 (en)	2013-05-28	2014-12-04	Israel Barken	Adoptive cell therapy with specific regulatory lymphocytes
US20160235842A1 (en)	2013-07-15	2016-08-18	The Board Of Trustees Of The Leland Stanford Junior University	Medical uses of cd38 agonists
WO2015067570A2 (en)	2013-11-06	2015-05-14	Boehringer Ingelheim International Gmbh	Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents
TWI670283B (en)	2013-12-23	2019-09-01	美商建南德克公司	Antibodies and methods of use
ES2711498T3 (en)	2014-02-14	2019-05-06	Cellectis	Immunotherapy cells designed by genetic engineering to direct an antigen present in immune cells and pathological cells
US9732154B2 (en)	2014-02-28	2017-08-15	Janssen Biotech, Inc.	Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en)	2014-02-28	2017-03-28	Janssen Biotech, Inc.	Combination therapies with anti-CD38 antibodies
WO2015195555A1 (en)	2014-06-16	2015-12-23	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
EP3154581B1 (en)	2014-06-16	2019-02-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
US9499514B2 (en)	2014-07-11	2016-11-22	Celgene Corporation	Antiproliferative compounds and methods of use thereof
MA39070A1 (en)*	2014-07-31	2017-11-30	Sanofi Sa	Anti-cd38 antibodies specific for the treatment of human cancers
ES2890669T3 (en)	2014-09-09	2022-01-21	Janssen Biotech Inc	Combination therapies with anti-CD38 antibodies
SG11201704390PA (en)	2014-12-04	2017-06-29	Janssen Biotech Inc	Anti-cd38 antibodies for treatment of acute myeloid leukemia
MA41555A (en)	2015-02-17	2017-12-26	Millennium Pharm Inc	POLYTHERAPY FOR CANCER TREATMENT
KR102602754B1 (en)	2015-05-20	2023-11-14	얀센 바이오테크 인코포레이티드	Anti-CD38 antibodies for treating light chain amyloidosis and other CD38-positive hematological malignancies
CN107708734B (en)	2015-06-22	2022-01-11	詹森生物科技公司	Combination therapy of heme malignancies with anti-CD 38 antibodies and survivin inhibitors
SMT202400127T1 (en)	2015-06-24	2024-05-14	Janssen Biotech Inc	Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
US20170044265A1 (en)	2015-06-24	2017-02-16	Janssen Biotech, Inc.	Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CN107921050A (en)	2015-06-29	2018-04-17	阿布拉科斯生物科学有限公司	Use the method for nano particle MTOR inhibitor conjoint therapy treatment haematological malignancies
ES2862425T3 (en)*	2015-11-03	2021-10-07	Janssen Biotech Inc	Subcutaneous formulations of anti-CD38 antibodies and their uses
US10781261B2 (en)	2015-11-03	2020-09-22	Janssen Biotech, Inc.	Subcutaneous formulations of anti-CD38 antibodies and their uses
US20170121417A1 (en)*	2015-11-03	2017-05-04	Janssen Biotech, Inc.	Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
JP2019527678A (en)	2016-06-28	2019-10-03	ユーエムセー・ユトレヒト・ホールディング・ベー・フェー	Treatment of IgE-mediated diseases with antibodies that specifically bind to CD38
US20180117150A1 (en)	2016-11-01	2018-05-03	Janssen Biotech, Inc.	Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
US11622961B2 (en)	2017-05-18	2023-04-11	Tesaro, Inc.	Combination therapies for treating cancer
MA50514A (en)	2017-10-31	2020-09-09	Janssen Biotech Inc	HIGH-RISK MULTIPLE MYELOMA TREATMENT METHODS
MX2020010144A (en)	2018-03-28	2020-12-07	Takeda Pharmaceuticals Co	Subcutaneous dosing of anti-cd38 antibodies.
US20190298827A1 (en)*	2018-04-03	2019-10-03	Janssen Biotech, Inc.	Methods of Treating Multiple Myeloma
KR20210011002A (en)	2018-05-16	2021-01-29	얀센 바이오테크 인코포레이티드	Methods of treating cancer and methods of improving the efficacy of T-cell reinduction therapeutics
EP3867275A2 (en)	2018-10-17	2021-08-25	Janssen Biotech, Inc.	Method of providing subcutaneous administration of anti-cd38 antibodies
EA202191352A1 (en)*	2018-11-13	2021-08-11	Янссен Байотек, Инк.	CONTROL OF THE CONTENT OF MICROELEMENTS-METALS DURING THE PRODUCTION OF ANTIBODIES TO CD38
WO2020170211A1 (en)	2019-02-22	2020-08-27	Janssen Biotech, Inc.	Methods of treating newly diagnosed multiple myeloma with a combination of an antibody that specifically binds cd38, lenalidomide and dexamethasone
US20200308297A1 (en)	2019-03-28	2020-10-01	Janssen Biotech, Inc.	Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
US20200316197A1 (en)*	2019-03-28	2020-10-08	Janssen Biotech, Inc.	Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone
US20200330593A1 (en)*	2019-03-28	2020-10-22	Janssen Biotech, Inc.	Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone
WO2020194243A1 (en)*	2019-03-28	2020-10-01	Janssen Biotech, Inc.	Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with lenalidomide and dexamethasone
US20200308296A1 (en)*	2019-03-28	2020-10-01	Janssen Biotech, Inc.	Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
US20200392242A1 (en)	2019-04-19	2020-12-17	Janssen Biotech, Inc.	Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20200397896A1 (en)	2019-04-19	2020-12-24	Janssen Biotech, Inc.	Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20200405854A1 (en)	2019-04-19	2020-12-31	Janssen Biotech, Inc.	Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20220401465A1 (en)	2019-06-04	2022-12-22	Shanghaitech University	Uses of nad+ and/or nad+ inhibitors and/or nad+ agonists and combination preparation thereof
US20220275090A1 (en)	2021-02-22	2022-09-01	Janssen Biotech, Inc.	Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors

2016
- 2016-11-01ESES16862791Tpatent/ES2862425T3/enactiveActive
- 2016-11-01EPEP24218846.4Apatent/EP4516319A3/enactivePending
- 2016-11-01CACA3233159Apatent/CA3233159A1/enactivePending
- 2016-11-01RSRS20210319Apatent/RS61651B1/enunknown
- 2016-11-01MAMA53356Apatent/MA53356B1/enunknown
- 2016-11-01MAMA43187Apatent/MA43187B1/enunknown
- 2016-11-01JPJP2018543011Apatent/JP7027321B2/enactiveActive
- 2016-11-01MYMYPI2018701739Apatent/MY202415A/enunknown
- 2016-11-01TWTW112112501Apatent/TWI838196B/enactive
- 2016-11-01SMSM20210192Tpatent/SMT202100192T1/enunknown
- 2016-11-01DKDK20215879.6Tpatent/DK3827845T3/enactive
- 2016-11-01ESES20215879Tpatent/ES2912729T3/enactiveActive
- 2016-11-01EAEA201891083Apatent/EA201891083A1/enunknown
- 2016-11-01SMSM20220243Tpatent/SMT202200243T1/enunknown
- 2016-11-01HUHUE16862791Apatent/HUE053366T2/enunknown
- 2016-11-01EPEP22165016.1Apatent/EP4085929A1/enactivePending
- 2016-11-01TWTW105135346Apatent/TWI724048B/enactive
- 2016-11-01AUAU2016350717Apatent/AU2016350717B2/enactiveActive
- 2016-11-01PTPT168627917Tpatent/PT3370770T/enunknown
- 2016-11-01DKDK16862791.7Tpatent/DK3370770T3/enactive
- 2016-11-01CNCN201680077740.2Apatent/CN108472369A/enactivePending
- 2016-11-01SGSG11201803678SApatent/SG11201803678SA/enunknown
- 2016-11-01EPEP20215879.6Apatent/EP3827845B1/enactiveActive
- 2016-11-01BRBR112018008901Apatent/BR112018008901A8/enactiveSearch and Examination
- 2016-11-01CRCR20180251Apatent/CR20180251A/enunknown
- 2016-11-01PLPL16862791Tpatent/PL3370770T3/enunknown
- 2016-11-01WOPCT/US2016/059893patent/WO2017079150A1/ennot_activeCeased
- 2016-11-01LTLTEP20215879.6Tpatent/LT3827845T/enunknown
- 2016-11-01USUS15/340,290patent/US10385135B2/enactiveActive
- 2016-11-01PTPT202158796Tpatent/PT3827845T/enunknown
- 2016-11-01KRKR1020187015075Apatent/KR20180067693A/ennot_activeCeased
- 2016-11-01LTLTEP16862791.7Tpatent/LT3370770T/enunknown
- 2016-11-01PEPE2018000731Apatent/PE20181365A1/enunknown
- 2016-11-01NZNZ780958Apatent/NZ780958A/enunknown
- 2016-11-01TWTW110112466Apatent/TWI760170B/enactive
- 2016-11-01MXMX2018005613Apatent/MX387587B/enunknown
- 2016-11-01SISI201631078Tpatent/SI3370770T1/enunknown
- 2016-11-01PLPL20215879Tpatent/PL3827845T3/enunknown
- 2016-11-01EAEA202190808Apatent/EA202190808A2/enunknown
- 2016-11-01MDMDE20210542Tpatent/MD3827845T2/enunknown
- 2016-11-01SISI201631528Tpatent/SI3827845T1/enunknown
- 2016-11-01TWTW113104998Apatent/TW202444413A/enunknown
- 2016-11-01EPEP16862791.7Apatent/EP3370770B1/ennot_activeRevoked
- 2016-11-01HRHRP20220680TTpatent/HRP20220680T1/enunknown
- 2016-11-01RSRS20220396Apatent/RS63210B1/enunknown
- 2016-11-01HRHRP20210274TTpatent/HRP20210274T1/enunknown
- 2016-11-01CACA3004152Apatent/CA3004152C/enactiveActive
- 2016-11-01MDMDE20180897Tpatent/MD3370770T2/enunknown
- 2016-11-01TWTW111112771Apatent/TWI800341B/enactive
- 2016-11-01CNCN202510129731.4Apatent/CN119950704A/enactivePending
- 2016-11-01PHPH1/2018/500950Apatent/PH12018500950B1/enunknown
- 2016-11-01CNCN202510129733.3Apatent/CN119950705A/enactivePending
- 2016-11-03ARARP160103354Apatent/AR106582A1/ennot_activeApplication Discontinuation
2018
- 2018-05-01ILIL259075Apatent/IL259075A/enunknown
- 2018-05-02NINI201800056Apatent/NI201800056A/enunknown
- 2018-05-03MXMX2021014956Apatent/MX2021014956A/enunknown
- 2018-05-03MXMX2021014955Apatent/MX2021014955A/enunknown
- 2018-05-03SVSV2018005683Apatent/SV2018005683A/enunknown
- 2018-05-03CLCL2018001202Apatent/CL2018001202A1/enunknown
- 2018-05-28COCONC2018/0005616Apatent/CO2018005616A2/enunknown
- 2018-05-30ECECIEPI201840758Apatent/ECSP18040758A/enunknown
2019
- 2019-07-02USUS16/460,754patent/US20200002433A1/ennot_activeAbandoned
- 2019-11-26ZAZA2019/07815Apatent/ZA201907815B/enunknown
2020
- 2020-04-03USUS16/840,153patent/US11566079B2/enactiveActive
- 2020-07-13USUS16/927,947patent/US11732051B2/enactiveActive
- 2020-12-09USUS17/116,822patent/US11708419B2/enactiveActive
- 2020-12-09USUS17/116,835patent/US11708420B2/enactiveActive
2021
- 2021-04-02JPJP2021063314Apatent/JP7169396B2/enactiveActive
- 2021-04-06CYCY20211100294Tpatent/CY1124004T1/enunknown
2022
- 2022-06-10CYCY20221100407Tpatent/CY1125241T1/enunknown
- 2022-09-26JPJP2022152551Apatent/JP7374275B2/enactiveActive
2023
- 2023-06-05USUS18/329,562patent/US20240092927A1/enactivePending
- 2023-09-29AUAU2023237196Apatent/AU2023237196A1/enactivePending
- 2023-10-24JPJP2023182287Apatent/JP2024010079A/enactivePending
2025
- 2025-05-05USUS19/198,946patent/US20250270342A1/enactivePending

Publication number	Publication date
CY1125241T1 (en)	2025-03-28
JP2018537525A (en)	2018-12-20
TWI800341B (en)	2023-04-21
KR20180067693A (en)	2018-06-20
US11708419B2 (en)	2023-07-25
ES2862425T3 (en)	2021-10-07
ECSP18040758A (en)	2018-06-30
TWI838196B (en)	2024-04-01
TWI724048B (en)	2021-04-11
AU2023237196A1 (en)	2023-10-26
MA53356A (en)	2021-06-02
CA3233159A1 (en)	2017-05-11
EP4516319A2 (en)	2025-03-05
DK3370770T3 (en)	2021-03-01
TW202444413A (en)	2024-11-16
EP3370770A4 (en)	2019-06-12
US11708420B2 (en)	2023-07-25
SMT202100192T1 (en)	2021-05-07
CY1124004T1 (en)	2022-05-27
JP7169396B2 (en)	2022-11-10
MY202415A (en)	2024-04-27
JP7027321B2 (en)	2022-03-01
CA3004152C (en)	2024-04-16
RS63210B1 (en)	2022-06-30
CR20180251A (en)	2018-08-06
US20200002433A1 (en)	2020-01-02
LT3370770T (en)	2021-04-12
EP4085929A1 (en)	2022-11-09
EP3827845A1 (en)	2021-06-02
DK3827845T3 (en)	2022-05-23
SI3370770T1 (en)	2021-03-31
MA53356B1 (en)	2022-05-31
EP4516319A3 (en)	2025-05-07
JP2021119137A (en)	2021-08-12
AR106582A1 (en)	2018-01-31
MD3370770T2 (en)	2021-05-31
SMT202200243T1 (en)	2022-07-21
JP2024010079A (en)	2024-01-23
RS61651B1 (en)	2021-04-29
US20240092927A1 (en)	2024-03-21
NZ742135A (en)	2024-10-25
US11732051B2 (en)	2023-08-22
MA43187B1 (en)	2021-02-26
TW202344268A (en)	2023-11-16
EP3370770A1 (en)	2018-09-12
TW202245840A (en)	2022-12-01
US20210107991A1 (en)	2021-04-15
PT3827845T (en)	2022-07-08
AU2016350717A1 (en)	2018-05-17
CL2018001202A1 (en)	2018-10-12
MX2021014956A (en)	2022-02-03
PL3370770T3 (en)	2021-07-05
MD3827845T2 (en)	2022-09-30
MX387587B (en)	2025-03-18
IL259075A (en)	2018-06-28
US20200339701A1 (en)	2020-10-29
JP7374275B2 (en)	2023-11-06
SI3827845T1 (en)	2022-06-30
PH12018500950B1 (en)	2023-09-20
EA201891083A1 (en)	2018-12-28
JP2022185004A (en)	2022-12-13
PT3370770T (en)	2021-02-22
CA3004152A1 (en)	2017-05-11
NZ780958A (en)	2025-06-27
ES2912729T3 (en)	2022-05-27
HRP20220680T1 (en)	2022-07-08
PE20181365A1 (en)	2018-08-27
HRP20210274T1 (en)	2021-06-11
MX2021014955A (en)	2022-02-03
TW201726168A (en)	2017-08-01
WO2017079150A1 (en)	2017-05-11
MX2018005613A (en)	2018-09-21
AU2016350717B2 (en)	2023-08-10
US10385135B2 (en)	2019-08-20
MA43187A (en)	2018-09-12
US20170121414A1 (en)	2017-05-04
PL3827845T3 (en)	2022-07-11
SV2018005683A (en)	2018-08-31
BR112018008901A8 (en)	2019-02-26
US20250270342A1 (en)	2025-08-28
BR112018008901A2 (en)	2018-11-06
CN119950704A (en)	2025-05-09
LT3827845T (en)	2022-06-10
NI201800056A (en)	2018-08-30
HUE053366T2 (en)	2021-06-28
EP3827845B1 (en)	2022-03-30
CN108472369A (en)	2018-08-31
US11566079B2 (en)	2023-01-31
TWI760170B (en)	2022-04-01
PH12018500950A1 (en)	2018-11-12
CO2018005616A2 (en)	2018-05-31
US20200231697A1 (en)	2020-07-23
ZA201907815B (en)	2020-12-23
TW202144006A (en)	2021-12-01
US20210095042A1 (en)	2021-04-01
CN119950705A (en)	2025-05-09
EP3370770B1 (en)	2021-01-20
EA202190808A2 (en)	2021-12-31

Publication	Publication Date	Title
ZA201907815B (en)	2020-12-23	Subcutaneous formulations of anti-cd38 antibodies and their uses
IL304117A (en)	2023-09-01	Anti-pvrig antibodies and methods of use
IL259495A (en)	2018-07-31	Antibodies and methods of use thereof
IL257636A (en)	2018-04-30	Anti-tigit antibodies and methods of use
IL254887A0 (en)	2017-12-31	Anti-sortilin antibodies and methods of use thereof
SG11201803567XA (en)	2018-05-30	Anti-siglec-9 antibodies and methods of use thereof
SG10201912150TA (en)	2020-02-27	Anti-trem2 antibodies and methods of use thereof
EP3310378C0 (en)	2024-01-24	Anti-cll-1 antibodies and methods of use
IL259681A (en)	2018-07-31	Novel anti-claudin antibodies and methods of use
ZA202001985B (en)	2022-12-21	Anti-htra1 antibodies and methods of use thereof
PL3110447T3 (en)	2020-10-19	Anti-egfr antibody and uses of same

Movatterモバイル変換

SG11201803678SA - Subcutaneous formulations of anti-cd38 antibodies and their uses - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=58634408

Family Applications (1)

Country Status (39)

Families Citing this family (53)

Family Cites Families (169)

Also Published As

Similar Documents